What's Behind Grail Stock's Wild Ride in 2026, and What Can Investors Expect in 2027? | The Motley Fool
The multi-cancer early detection test company’s volatility is likely to continue next year.
By Lee Samaha –
Key Points
-
Food and Drug Administration approval is seen as a gateway to potential coverage by Medicare and commercial insurers for Grail’s Galleri test.
-
Pricing remains a key watch item, as it’s far from clear how commercial insurers will value the test.
Grail (GRAL -5.33%) stock has been highly volatile in 2026, and that trend looks set to continue next year as well. Management expects its multi-cancer early detection (MCED) test, Galleri, to be approved in the first quarter of 2027, but that’s only part of the story. Here’s what investors need to know and where the stock could be heading next year.
Grail’s ups and downs in 2026
The company finalized its pre-market approval submission for Galleri in late January, only to follow up with disappointing top-line results from its landmark three-year trial of Galleri with England’s National Health Service (NHS). The trial failed to meet its primary endpoint of a statistically significant reduction in the diagnosis of late-stage (III and IV) cancers in a population of 142,000.
$99.25-$5.59 (-5.33%)
NASDAQ · As of 4:00 PM ET 11/20/26
The principle was that Galleri would detect cancers at an early stage (I and II), leading to less expensive, less intrusive, and more comfortable treatments and, ultimately, better patient outcomes. The trial’s overall failure obviously raised concerns about FDA approval and, more importantly, insurer coverage of the test. That’s the crash you can see in the stock in February.
Grail builds confidence
While the trial’s result was disappointing across the more than 50 cancers it tests for, it did demonstrate more compelling data across the 12 most deadly cancers (including anus, bladder, colorectal, head and neck, lung, ovary, pancreas, and stomach) that cause two-thirds of the deaths in the U.S.
As such, management continued to build the case that the Galleri test data were compelling enough to convince the FDA to approve the test and spur insurer adoption. It’s a case that management highlighted at the American Society of Clinical Oncology (ASCO) meeting at the end of May, when outlining both the NHS trial and a smaller 35,000-patient trial in the U.S. and Canada.
Image source: Getty Images.
The stock then soared in September after an FDA panel voted in favor of Galleri’s safety, effectiveness, and benefit, paving the way for FDA marketing approval in 2027.
The case for Galleri
The ultimate adoption of Galleri by insurers and medical bodies relies on a somewhat complex set of factors and criteria that don’t lend themselves to a binary assessment of trial results. For example, a medical insurer is highly likely to conduct a cost-benefit analysis, weighing the benefits of early detection against the test’s cost relative to alternative tests and the cost of false positives.
False positives not only cause significant and unnecessary stress in a patient population, but they also create unnecessary costs, as the positively tested patients will undergo more costly and specific diagnostic testing to determine whether they have cancer with a higher degree of accuracy.
Readers interested in more detail on such matters can read an analysis of the two Galleri trial results in a previous article. Suffice it to say that it isn’t simply a matter of the FDA approving the Galleri test and insurers adopting it en masse; the test also needs to demonstrate its commercial viability to insurers.
Image source: Getty Images.
Medicare coverage
In addition, management has high hopes that Medicare will reimburse Galleri under the Nancy Sewell ACT, which allows coverage and payment for FDA-approved MCED tests if the Centers for Medicare & Medicaid Services (CMS) “determines such coverage is appropriate.”
Management is in contact with the CMS and expects it to initiate a National Coverage Analysis (NCA) following FDA approval (hopefully in early 2027), culminating in a National Coverage Determination (NCD) about a year later.
Grail in 2027
Therefore, the sequence of events next year is FDA approval, which then opens up more detailed conversations with commercial payers and insurers, and initiation of an NCA by the CMS. Ultimately, the key to Grail and Galleri’s future may not be commercial payers’ decision to adopt the test; it may come down to the price they are willing to pay for it. Grail’s management thinks the Galleri test will ultimately settle in a $500 to $600 range, with Wall Street analysts modeling $574 in 2029.
That would be a favorable outcome for Grail, but there’s a long way to go before it takes place, and the first step is FDA approval.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 719%* — a market-crushing outperformance compared to 192% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of November 22, 2026.
